Literature DB >> 26994106

A less invasive method for orthotopic injection of breast cancer cells into the mouse mammary gland.

Luz E Tavera-Mendoza1, Myles Brown1,2.   

Abstract

Breast cancer is the most common type of cancer diagnosed in women, and the second most common cause of cancer-related deaths in women in North America. The use of laboratory mice in research is an essential tool for the study of breast cancer biology and for pre-clinical therapeutic development. While subcutaneous flank injections of cancer cells are widely used for studying breast cancer biology and for exploring novel therapies, orthotopic xenografting of tumors into the mouse mammary gland allow for the study of breast cancers in a biologically relevant microenvironment. In this study we report a modification of the method of orthotopic injections of cancer cells into the mouse mammary gland which greatly reduces the effects of surgery in mice including decreased wound size, procedure time and anesthesia. It also removes the risk of accidentally puncturing the peritoneal cavity. Consequently post-operative animal handling and stress are significantly reduced. All of these advantages are present without compromising procedure success rate. Therefore, this modification makes orthotopic mammary gland injection a more efficient procedure and greatly improves animal welfare.

Entities:  

Keywords:  surgery; tumor model

Mesh:

Year:  2016        PMID: 26994106     DOI: 10.1177/0023677216640706

Source DB:  PubMed          Journal:  Lab Anim        ISSN: 0023-6772            Impact factor:   2.471


  8 in total

1.  Orthotopic Breast Cancer Model to Investigate the Therapeutic Efficacy of Nanobody-Targeted Photodynamic Therapy.

Authors:  Marion M Deken; Shadhvi S Bhairosingh; Alexander L Vahrmeijer; Sabrina Oliveira
Journal:  Methods Mol Biol       Date:  2022

2.  Single-Cell Analysis Unveils the Role of the Tumor Immune Microenvironment and Notch Signaling in Dormant Minimal Residual Disease.

Authors:  Mahnaz Janghorban; Yuchen Yang; Na Zhao; Clark Hamor; Tuan M Nguyen; Xiang H-F Zhang; Jeffrey M Rosen
Journal:  Cancer Res       Date:  2022-03-01       Impact factor: 13.312

3.  Stat3 modulates chloride channel accessory protein expression in normal and neoplastic mammary tissue.

Authors:  Katherine Hughes; Maximilian Blanck; Sara Pensa; Christine J Watson
Journal:  Cell Death Dis       Date:  2016-10-06       Impact factor: 8.469

4.  Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.

Authors:  Zhen Zhao; Yuanke Li; Ravi Shukla; Hao Liu; Akshay Jain; Ashutosh Barve; Kun Cheng
Journal:  Theranostics       Date:  2019-06-09       Impact factor: 11.556

5.  Genomic Instability Is an Early Event in Aluminium-Induced Tumorigenesis.

Authors:  Stefano J Mandriota; Mirna Tenan; Adeline Nicolle; Julia D Jankowska; Paolo Ferrari; Jean-Christophe Tille; Mary-Anne Durin; Catherine M Green; Sebastien Tabruyn; Daniela Moralli; André-Pascal Sappino
Journal:  Int J Mol Sci       Date:  2020-12-07       Impact factor: 5.923

6.  The immune environment of the mammary gland fluctuates during post-lactational regression and correlates with tumour growth rate.

Authors:  Jessica Hitchcock; Katherine Hughes; Sara Pensa; Bethan Lloyd-Lewis; Christine J Watson
Journal:  Development       Date:  2022-04-29       Impact factor: 6.862

7.  Polarity protein SCRIB interacts with SLC3A2 to regulate proliferation and tamoxifen resistance in ER+ breast cancer.

Authors:  Yasuhiro Saito; Shiori Matsuda; Naomi Ohnishi; Keiko Endo; Sanae Ashitani; Maki Ohishi; Ayano Ueno; Masaru Tomita; Koji Ueda; Tomoyoshi Soga; Senthil K Muthuswamy
Journal:  Commun Biol       Date:  2022-05-02

8.  Friend leukemia virus integration 1 is a predictor of poor prognosis of breast cancer and promotes metastasis and cancer stem cell properties of breast cancer cells.

Authors:  Xu Yan; Yu Yu; Lingyu Li; Naifei Chen; Wei Song; Hua He; Jie Dong; Xiangliang Liu; Jiuwei Cui
Journal:  Cancer Med       Date:  2018-06-04       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.